登录

Jiabao Drug Bank Raises ¥100 Million in Pre-Series A Funding Round

作者: Mailman 2021-08-23 16:34
嘉葆药银
企业数据由 动脉橙 提供支持
小分子创新药研发商 | PreA轮 | 运营中
中国-四川
2021-08-08
融资金额:RMB¥1亿
鼎祥资本
查看

(VCBeat) Aug. 08, 2021 -- Chengdu Jiabao Drug Bank Pharma Technology Co., Ltd. ("Jiabao Drug Bank") today announced the closing of Pre-Series A financing of 100 million yuan. Jiabao Drug Bank is a company focused on innovative small molecule development in the fields of infection, cancer and autoimmune diseases. Led by Academician Wei Yuquan, it was established in Chengdu, Sichuan province in 2019. The company is committed to the development of class I innovative drugs in clinically urgent demands. 


The latest round is led by Dingxiang Capital with participation from Probe Capital. The funds raised will be used to promote the clinical development of drugs, improve the research and development team, and expand the product pipeline globally.


Just as this round was completed, Jiabao Drug Bank also announced the establishment of a wholly-owned subsidiary in Shanghai Zhangjiang, which will focus on clinical research of drugs related to the treatment of advanced solid tumors.


JDB0131, one of the core products of Jiabao Drug Bank, has entered the phase I clinical trial. It is one of the safest drugs under clinical research for the treatment of drug-resistant tuberculosis (TB). JDB0131 has shown high safety in clinical trials, with no drug-related adverse reactions in enrolled subjects. JDB0131 is expected to enter the critical clinical stage in 2022 and apply for the certification of breakthrough therapy. It is expected to become China's first self-developed and marketed drug for drug-resistant TB, which will greatly alleviate the existing difficulties in this indication and truly provide a treatment that is affordable, safe and reliable for patients to fight drug-resistant TB.


In addition to JDB0131, Jiabao Drug Bank's main pipeline includes JDB153, the world's first drug for tumor immunity and anti-tumor angiogenesis that can save patients when anti-PD-1 therapy fails. JDB175, a highly selective BTK inhibitor with excellent penetration effect towards brain; JDB383, the only CSF1R inhibitor verified by the PDX model in the world. Those drugs all have the advantages of clinical urgent need with fewer competing products in the market.


>>>>

About Dingxiang Capital


Dingxiang Capital is a professional investment management platform set up by De Sheng Group, one of China's top 500 enterprises, with a registered capital of 500 million yuan. At present, the company has invested in aerospace, military, polymer materials, bio-medicine, pan-entertainment, TMT and national strategic emerging industries. Up to now, it has managed and participated in the management of 16 funds, with a total investment amount of about 8.2 billion yuan and a fund management scale of more than 11 billion yuan.


>>>>

About Probe Capital


Probe Capital is an incubating, investment and financing platform focusing on the medical and life technology industry. Its founders are from well-known domestic medical VC and have completed billions of RMB financing. Probe Capital is the leading FA institution in China's medical and health field.

相关赛道 化学制药
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】可瑞生物完成Pre-A+轮融资,加速推进TCR创新药布局

QureBio Raises ¥10M in Pre-B Round of Financing

【首发】翱锐生物完成近亿元B轮融资,建设国内最全的消化道癌症早筛平台

OnKure:表观遗传疗法治疗癌症,两年内获融资1.09亿美元

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Kangle Weishi Receives ¥1.015 Billion pre-IPO Investment

2021-08-23
下一篇

Chemical.AI Extends Series A Financing by Additional $15 Million

2021-08-23